Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.

@article{Hernndez1991EvidenceOA,
  title={Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.},
  author={R. Hern{\'a}ndez Hern{\'a}ndez and J. G. Guerrero Pajuelo and A. Carvajal and M. C. Armas Padilla and M. J. Armas de Hern{\'a}ndez and O. Barrag{\'a}n and J. J. Boada Boada},
  journal={American heart journal},
  year={1991},
  volume={121 1 Pt 2},
  pages={
          395-401
        }
}
  • R. Hernández Hernández, J. G. Guerrero Pajuelo, +4 authors J. J. Boada Boada
  • Published 1991
  • Medicine
  • American heart journal
  • Eighteen patients with a mean age of 54.7 years were included in the study. All patients had a diagnosis of mild or moderate essential hypertension (sitting diastolic blood pressure of 96 to 114 mm Hg). The study design was single blind and in two phases: phase I, placebo (4 weeks), and phase II, the active treatment (8 weeks) with increasing doses, if needed, of doxazosin every 2 weeks (1, 2, 4, and 8 mg/day). Results show that doxazosin has an antihypertensive effect that is dose dependent… CONTINUE READING
    19 Citations
    Effects of antihypertensive treatment on platelet function in essential hypertension.
    • 17
    Is the Effect of Antihypertensive Drugs on Platelet Aggregability and Fibrinolysis Clinically Relevant?
    • Roberto Fogari, A. Zoppi
    • Medicine
    • American journal of cardiovascular drugs : drugs, devices, and other interventions
    • 2005
    • 17

    References

    SHOWING 1-10 OF 22 REFERENCES
    Efficacy and safety of doxazosin in hypertension therapy.
    • K. Hayduk
    • Medicine
    • The American journal of cardiology
    • 1987
    • 26